KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Revenue (2017 - 2025)

Sarepta Therapeutics has reported Revenue over the past 12 years, most recently at $442.9 million for Q4 2025.

  • For Q4 2025, Revenue fell 32.73% year-over-year to $442.9 million; the TTM value through Dec 2025 reached $2.2 billion, up 15.58%, while the annual FY2025 figure was $2.2 billion, 15.58% up from the prior year.
  • Revenue for Q4 2025 was $442.9 million at Sarepta Therapeutics, up from $399.4 million in the prior quarter.
  • Over five years, Revenue peaked at $1.1 billion in Q4 2023 and troughed at $22.0 million in Q1 2023.
  • A 5-year average of $363.3 million and a median of $336.1 million in 2023 define the central range for Revenue.
  • Biggest five-year swings in Revenue: tumbled 89.56% in 2023 and later surged 1778.95% in 2024.
  • Year by year, Revenue stood at $201.5 million in 2021, then surged by 285.69% to $777.0 million in 2022, then surged by 38.75% to $1.1 billion in 2023, then plummeted by 38.93% to $658.4 million in 2024, then plummeted by 32.73% to $442.9 million in 2025.
  • Business Quant data shows Revenue for SRPT at $442.9 million in Q4 2025, $399.4 million in Q3 2025, and $611.1 million in Q2 2025.